;
GAiT joins CCRM on their latest podcast to discuss the clinical potential of induced Pluripotent Stem Cells
Commercializing Living Therapies with CCRM: Unlocking the potential of induced pluripotent stem...
Show Commercializing Living Therapies with CCRM, Ep Unlocking the potential of induced pluripotent stem cells - Dec 14, 2022
podcasts.apple.com
With a very heavy heart, we announce the passing of our CEO and co-founder, Susan Solomon, following a long battle with ovarian cancer. We owe all that NYSCF has accomplished to Susan, and no words can express our gratitude and awe for her catalytic impact on stem cell research.
With a very heavy heart, we announce the passing of our CEO and co-founder, Susan Solomon, following a long battle with ovarian cancer. We owe all that NYSCF has accomplished to Susan, and no words can express our gratitude and awe for her catalytic impact on stem cell research.
Great panel on regulatory futures for CGT from various perspectives - Niloofar Davoodi, @TakedaPharma, Ian Rees, @MHRAgovuk, Michael von Forstner, @biogen and led by Jacqueline Barry, @CGTCatapult
#advancedtherapieseurope #ate2022 #ate22 #celltherapy #regulatory
Great panel on regulatory futures for CGT from various perspectives - Niloofar Davoodi, @TakedaPharma, Ian Rees, @MHRAgovuk, Michael von Forstner, @biogen and led by Jacqueline Barry, @CGTCatapult
#advancedtherapieseurope #ate2022 #ate22 #celltherapy #regulatory
Companies developing iPSC-based cell therapies
Companies developing iPSC-based cell therapies
Characterization of advanced therapies: leveraging advanced #analytics to avoid #FDA holds
Find out the key #assay types needed for successful characterization of #cellandgenetherapy
Read the FastFacts poster, or watch the video, here: http://bit.ly/3AxQmMz
#celltherapy
https://advancedtherapiesweek.phacilitate.com/
